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The Role of StarD13 in Breast Cancer Cell Proliferation  
and Motility 
 
Samer J. Hanna 
 
                        ABSTRACT 
 
 
Breast cancer is one of the most commonly diagnosed cancers in women around the 
world. In general, the more aggressive the tumor, the more rapidly it grows and the 
more likely it metastasizes. Cell migration, is a complex process, which requires the 
dynamic regulation of actin cytoskeleton. Members of the Rho subfamily of small GTP-
binding proteins (GTPases) play a central role in breast cancer cell motility. The switch 
between active GTP-bound and inactive GDP-bound state is regulated by Guanine 
nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and Guanine-
nucleotide dissociation inhibitors (GDIs). Here we study the role of StarD13, a newly 
identified Rho-GAP that specifically inhibits the function of RhoA and Cdc42. We aim 
to investigate its role in breast cancer proliferation and metastasis. The level of 
expression of this Rho-GAP in tumor tissues of different grades is assayed using 
immunohistochemistry. Moreover, the role of StarD13 in breast cancer cell lines is 
studied using two approaches. StarD13 is overexpressed using a StarD13-GFP 
construct, in the second approach StarD13 is knocked down using a specific siRNA. 
The effect on the activity of Rho-GTPases is observed using pull down activation assay, 
which confirmed StarD13 as a negative regulator for Rho and Cdc42 but not for Rac. 
Our results also showed that StarD13 plays a negative role in cellular proliferation. 
Moreover to investigate the role of StarD13 in cell motility, StarD13 knock down 
resulted in an inhibition of cell motility and cells were not able to detach their tail and 
move forward. Being a Rho-GAP and localizing to focal adhesions, we hypothesize that 
StarD13 is inhibiting Rho to allow the formation of Rac-dependent focal complexes and 
the detachment of focal adhesions for the cells to move forward. However, our results 
show that the knockdown of StarD13 seems to promote breast cancer cell invasion in 
vitro.  
 
Keywords: StarD13, Breast Cancer, Cell proliferation, Cell motility, Focal Adhesions, 
Cell invasion. 
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Chapter I 
LITERATURE REVIEW 
 
1.1. Breast Cancer 
 
1.1.1. Introduction 
 
 Breast cancer is one of the most commonly diagnosed cancers in women 
around the world. Ductal and lobular carcinomas are the two most frequent types 
of breast cancer. They can be either noninvasive referred to as in situ carcinoma, or 
invasive infiltrating carcinoma (Jiang, Enomoto, & Takahashi, 2009). The most 
important factor in predicting patient outcome is the stage of the disease. In 
general, the more aggressive the tumor, the more rapidly it grows and the more 
likely it metastasizes. However, there are many small breast cancers with a highly 
aggressive behavior that remain undertreated because there is no marker capable of 
identifying them (Kleer, et al., 2002).  
 
1.1.2. Classification of Breast Cancer 
 
According to the US National Cancer Institute, breast cancer can be classified 
into five progressive stages.  Stage 0 is referred to as carcinoma in situ, which can be 
either ductal carcinoma in situ (DCIS) or Lobular carcinoma in situ (LCIS). DCIS 
may become invasive in later stages of the tumor and spread to other tissues 
(Bombonati & Sgroi, 2011; Claus, Stowe, & Carter, 2001). Invasive breast carcinoma 
can be classified into progressive stages Ι through ΙV depending on its size and 
presence or absence at secondary sites, mainly lymph nodes. Inflammatory breast 
cancer (IBC) is a highly aggressive form of cancer that has disseminated to the dermal 
lymphatic systems reaching distant organs (van Golen, 2003).   
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1.1.3. Predisposition 
 
It is estimated that about 10% of breast cancer cases are associated with family 
history (Lacroix, Toillon, & Leclercq, 2004; Ripperger, Gadzicki, Meindl, & 
Schlegelberger, 2009). The two major high penetrance breast cancer susceptibility 
genes are BRCA1 and BRCA2. Individuals with mutations in these two genes are at 
high risk to develop breast, ovarian and other cancers. The risk estimates for 
developing breast cancer range from 20 to 40% and the age of diagnosis is much 
younger in comparison to sporadic cases (Bordeleau, et al., 2011; Lacroix, et al., 
2004).  The human genome is typically very stable and resists many genetic 
alterations required for cancer development. However, the increase in the rate of 
mutation causes genetic instability, which is characteristic of BRCA gene 
abnormalities. Both BRCA1 and BRCA2 are relatively long genes capable of 
accumulating hundreds of different mutations that can alter the function of their 
corresponding proteins that are involved in the loss of the DNA repair (Bordeleau, 
et al., 2011; Lacroix, et al., 2004; Ripperger, et al., 2009). 
In addition, there are several other predisposing susceptibility genes associated 
with an increased breast cancer risk. Such genes include ATM, TP53 and ARLTS1, 
which account only for a small portion of familial breast cancers (Ripperger, et al., 
2009). 
 
1.1.4. Tumor diagnosis and treatment 
 
Breast cancer prevalence increased dramatically throughout the past few years. 
However patients’ outcomes have improved due to the progress in major aspects of 
tumor diagnosis and treatment. Standard treatments include surgery, chemotherapy, 
radiation therapy, hormonal therapy and most recently targeted therapy (Stebbing, et 
al., 2012).   
Targeting the pathways that are involved in promoting and sustaining growth 
and invasion of cancer cells is critical to achieve effective treatment of breast cancer 
(Schlotter, Vogt, Allgayer, & Brandt, 2008). Three major prognostic markers are 
routinely used to help define breast cancer therapy: Estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth receptor (HER2). Recently, 
intensive effort has been employed in targeting key molecular markers involved in 
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tumor progression and prognosis in an attempt of developing practical, clinically 
relevant and effective treatment of patients (Hicks, 2012).  
 
1.1.4.1. Molecular targeted therapy 
 
During the past 25 years, targeting the estrogen receptor (ER) has been 
the most widely used molecular therapy approach in effectively curing and 
preventing breast cancer. Tamoxifen, a selective ER modulator is responsible 
for major improvements in survival rates and quality of life.  
Other important biomarkers for targeted therapy include human 
epidermal growth receptor (HER2) and vascular endothelial growth factor 
(VEGF). Trastuzumb and bevacizumab have demonstrated high specificity 
and have been shown to improve response rates and survival of breast cancer 
patients. Moreover, when used in combination with chemotherapy these dugs 
have been shown to significantly reduce the risk of recurrence in early stages 
(Hicks, 2012; Schlotter, et al., 2008). 
 
1.1.4.2. Signaling pathways as molecular therapy targets 
 
In attempt to circumvent the resistance to both endocrine and 
cytostatic treatments currently in use, treatment with growth factor pathway 
inhibitors and their downstream effector signaling pathways is being 
implemented. Such approaches may push towards radical improvements in 
the current therapeutic strategies for breast cancer patients. Such targeted 
therapies opt to inhibit cell cycle progression, signal transduction, angiogenesis 
and induce apoptosis or cell death (Figure 1) (Schlotter, et al., 2008) 
Breast cancer treatment targeting cell signaling pathways include: 
epidermal growth factor receptor (EGFR), G-protein-coupled receptor 
(GPCR), inhibitor of NF-ΚB kinase (IKK) tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), vascular epidermal growth factor receptor 
(VEGFR) and many others (Figure 1). Ultimately, such treatments result in 
modulating these critical cell-signaling pathways involved in cell survival, 
proliferation and motility (Hicks, 2012; Schlotter, et al., 2008).  
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Figure 1: Cell signaling pathways: targets for breast cancer treatment. Major 
potential targets include EGFR, HER2 modulating cellular proliferation, GPCR 
resulting in altered cell migration, TRAIL modifying pro and anti-apoptotic elements 
and VEGR affecting angiogenesis. Source: (Schlotter, et al., 2008) 
 
 
 
1.2. Cell survival, proliferation and apoptosis 
 
1.2.1. Cell cycle progression 
 
The link between cell survival, cell cycle and cell death has become an important 
molecular target in research throughout recent years. Normally the cell cycle of 
eukaryotic cells is divided into four non-overlapping phases. These include two 
preparatory gap phases G1 and G2 separated by DNA synthesis (S) phase and 
mitosis (M) phase (Maddika, et al., 2007) 
During G1 phase, the cell prepares itself for the later DNA synthesis phase. 
Cells in this phase are diploid (2n) and tend to grow in size and produce new proteins 
required in subsequent phases (Collins & Garrett, 2005; Maddika, et al., 2007).  
Following G1, the cell enters into S phase, in which DNA replication occurs. At 
the end of this phase each cell contains 2n chromosomes made up of two chromatids 
thus reaching a 4n DNA content (Maddika, et al., 2007; Schafer, 1998).  
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Before undergoing mitosis, cells carry on further growth and preparation and 
enter G2 phase.  At the end of this phase cells are now ready to proceed to the M 
phase.  
During M phase, cells undergo division or mitosis producing two daughter cells. 
These cells are diploid and genetically identical to each other and to the original 
mother cell.  Cells that stop dividing or are not actively cycling tend to exit the cell 
cycle into a quiescent phase G0.  (Collins & Garrett, 2005; Maddika, et al., 2007; 
Schafer, 1998) 
Checkpoints are present at the end of each phase of the cell cycle that allow the 
arrest and activation of repair mechanism in case of any malfunction (Schafer, 1998). 
After passing a checkpoint, the cell becomes irreversibly committed to the next phase 
(Park & Lee, 2003). DNA damage or other critical malfunctions can activate cell 
cycle arrest and may also trigger the apoptotic cascade pathway leading to cell death 
(Maddika, et al., 2007). Thus apoptosis plays an essential role during the cell cycle 
progression preventing the propagation of damaged or unwanted cells (Maddika, et 
al., 2007; Park & Lee, 2003).  
Regulated machinery exists to control the progression of the cell cycle to 
guarantee proper cell growth and proliferation. Cyclin-dependent kinases (CDKs) are 
key regulatory proteins that allow smooth transition from one phase to the other 
(Maddika, et al., 2007).  CDKs are serine/threonine kinases that are activated at 
particular stages of the cell cycle (Collins & Garrett, 2005). These proteins are 
positively regulated by binding to respective cyclins (Park & Lee, 2003). Activating 
cyclins are produced at each phase of the cell cycle; these bind to corresponding 
CDKs targeting them to the nucleus whereby catalyzing the process of cell division.  
Cyclins undergo a cyclic expression during the cell cycle. Typically, before entering a 
new phase, cyclin of the previous phase is degraded and the apprpriate cyclin of the 
next phase is synthesized. Thus, the level of cyclins present in different phases is 
variable; however, CDKs remain constant (Schafer, 1998; Vermeulen, Van 
Bockstaele, & Berneman, 2003). 
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1.2.2. PI3-Kinase/Akt pathway controls cell survival 
 
The Phosphatidylinositol 3-kinase (PI3-K) signaling pathway is one of the most 
important key survival pathways. It is activated by a myriad of cellular stimuli 
regulating fundamental cellular functions including proliferation, growth, gene 
transcription, cell cycle progression and apoptosis (Maddika, et al., 2007; Vivanco & 
Sawyers, 2002). These enzymes catalyze the phosphorylation of phosphoinositides and 
are classified according to substrate specificity and subunit organization (Dbouk & 
Backer, 2010; Engelman, Luo, & Cantley, 2006).  
Class IA PI3-Ks are obligate heterodimers composed of a catalytic subunit 
(p110) and regulatory subunits (p85, p55 and p50) and are activated downstream of 
receptor tyrosine kinases (RTKs). Class IB, activated downstream of G-protein 
coupled receptor (GPCRs), are dimers composed of a p110 catalytic subunit and p101 
or p87 regulatory subunits (Backer, 2008; Dbouk & Backer, 2010). Once activated PI3-
Ks phosphorylate membrane PI(4,5)P2 producing PI(3,4,5)P3. This in turn creates an 
important docking site for a wide range of downstream effectors having the plecktrin 
homology (PH) domain. Thus activating numerous intracellular proteins involved in 
various interconnected signaling pathways that regulate cell survival, proliferation 
and motility (Maddika, et al., 2007; Vivanco & Sawyers, 2002; Yip, et al., 2004)  
Akt is a downstream effector of PI3-K that controls cell survival through 
phospohrylating different substrates involved in survival and apoptotic pathways. It 
is recruited to the cell memrane through it PH domain which binds to PIP3. Akt is 
then phosphorylated and activated by PDK1 and mTOR kinases. One of the 
important targets of Akt is a pro-apoptotic protein of the Bcl-2 family, Bad. 
Phosphorylation of Bad by Akt activates and releases its associated apoptosis 
inhibitory protein thus blocking the apoptotic pathway (Figure2). Akt can also 
phosphorylate caspase-9 inducing a conformational change that results in the 
inhibition of its proteolytic activity, consequently blocking apoptosis and promoting 
cell survival (Maddika, et al., 2007; Vivanco & Sawyers, 2002) 
	   	  	   7	  
 
Figure 2: Akt promotes growth factor-related cell survival. Downstream of PI3-K, 
active Akt phosphorylates Bad making it dissociate from the inactive apoptosis 
inhibitory protein and losing its pro-apoptotic function. (Source: (Ramaswamy, et al., 
1999)  
 
 
1.2.3. Tumor suppressors and oncogenes 
 
It is believed that tumor suppressors have evolved probably to protect 
multicellular organisms from random mutations affecting various cellular functions. 
This hypothesis is supported by the fact that critical tumor suppressor proteins or 
pathways are mutated in most human cancers. Normally, these proteins exert a 
negative regulatory role on cellular growth and proliferation. Thus, inactivation 
through deletions or mutations may allow the development of a malignant phenotype 
(Viallet & Minna, 1990).  
p53 is one of the most important members of the tumor suppressor proteins 
(Levine, Momand, & Finlay, 1991). As a transcription factor, p53 has a crucial role in 
regulating cellular response to various stress signals through favoring cell cycle arrest, 
apoptosis or senescence. Consequently, in response to stress such as DNA damage, 
p53 enhances transcription of genes involved in cellular growth, apoptosis, 
angiogenesis and repair mechanisms. On the other hand, it can have direct non-
transcriptional activities promoting survival (Figure 3) (Brown, Lain, Verma, Fersht, & 
Lane, 2009).  
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Figure 3: The p53 pathway. p53 is located at the center of a complex web of 
biological interactions that translates stress signals into cell cycle arrest or apoptosis. 
Upstream signaling to p53 increases its level and activates its function as a transcription 
factor in response to a wide variety of stresses, whereas downstream components 
execute the appropriate cellular response. (Source: (Brown, et al., 2009).  
 
 
Oncogenes are gene products with putative role in promoting cellular 
transformation and initiating neoplastic growth. In general, mutations resulting in their 
constitutive activation of these proteins directly contribute to cellular transformation 
(Viallet & Minna, 1990). Oncogenes can be classified into different categories including 
growth factors, receptor tyrosine kinases, cytoplasmic kinases, regulatory GTPases and 
transcription factors (Croce, 2008). Consequently, the cellular location of these 
oncoproteins depicts their respective functions. For example, Ras proteins located in the 
inner membrane of the cell are involved in signal transduction. Others such as c-myc and 
c-jun are nuclear proteins implicated in transcription and regulation of the cell cycle 
(Evans, 1993; Maddika, et al., 2007). This implicates their cooperative role in surpassing 
growth leading to uncontrolled cell proliferation and ultimately carcinogenesis 
(Harrington, Fanidi, & Evan, 1994).  
Therefore, in most cancer systems the antagonistic relationship between the 
tumor suppressors and oncogenes is delineated by the inactivation of the former and the 
constitutive activation of the latter (Viallet & Minna, 1990).  
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1.2.4. Apoptotic pathways 
 
Apoptosis is a programmed cell death, which plays important roles in 
physiological processes including embryogenesis and immunology. Complex signaling 
pathways are involved in regulating apoptosis. There are two well-known distinct 
apoptotic pathways: the intrinsic pathway also known as p53-mitochondrial pathway; 
and the extrinsic pathway which is activated through the binding of external ligands to 
specific membrane receptors known as ‘death receptors’ (Munoz-Pinedo, 2012; Taylor, 
Cullen, & Martin, 2008).   
Mitochondrial intrinsic pathway is regulated by members of the Bcl-2 family of 
proteins. These include anti-apoptotic Bcl-2 and pro-apoptotic Bax and Bad proteins. 
Bcl-2 is known to be overexpressed in up to 80% of breast cancer patients. It is 
also associated with high expression of hormone receptors ER and PR.  Bcl-2 inhibits 
the process of apoptosis through regulating mitochondrial membrane permeability.  It 
inhibits the formation of secretory pores through which cytochrome c exit the 
mitochondria. Consequently, the assembly of caspases involved in the completing the 
apoptotic pathway is inhibited (Ruvolo, Deng, & May, 2001; Srivastava, et al., 1998).  
 Pro-apoptotic Bax and Bad proteins are responsible for the formation of pores 
through the membrane of the mitochondria leading to the release of cytochrome c. 
This in turn activates the assembly of caspases-3 and 9 resulting in the proteolytic 
cleavage of downstream PARP and triggering apoptosis (Munoz-Pinedo, 2012; 
Schlotter, et al., 2008).  	  	  
1.2.5. Altered cell growth and cancer 
 
 Disturbances in the homeostatic regulation of multiple signaling pathways result 
in altered cellular growth and consequently promote carcinogenesis. Typically, 
mutations within critical processes will affect a cascade of signaling pathways leading to 
reduced cell death, prolonged cell survival and uncontrolled proliferation (Maddika, et 
al., 2007).  
Disruption in the regulation of apoptosis prolongs the life of cells and thereby 
promoting carcinogenesis. Subsequently, apoptosis is inhibited in cancer cells, 
supposedly by the activation of anti-apoptotic proteins and the deregulation of the 
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homeostasis between tumor suppressors and oncogenes. The result is the prevention 
of cell death and prolonged survival, cancer cell characteristics (Schlotter, et al., 2008).  
In addition to inhibiting apoptotic pathways, mutations may result in the 
constitutive activation of survival pathways. Notably, PI3-K/Akt and Ras/MAPK 
pathways are frequently disrupted in most human cancers. These alterations prolong 
cell survival and play a major role not only in cell transformation and tumor 
development but also in resistance to cancer treatments (Vivanco & Sawyers, 2002). 
Being a highly organized and tightly regulated process, defects in the programmed 
regulation of cell cycle-progression can also result in cancerous growth and 
development (Collins & Garrett, 2005; Park & Lee, 2003). Oncogenes and tumor 
suppressor genes are known to be involved in mitogenic signal transduction affecting 
transcription and initiation of the cell cycle. Consequently, in transformed cells, many 
oncoproteins are always “turned on” and tumor suppressors or other inhibitory 
mechanisms are “turned off”.  P53, mdm2, pRb, p21 and many others are strictly 
involved in the regulation of the cell cycle. Hence, deregulation of these proteins 
promotes uncontrolled growth and development of neoplasia (Schafer, 1998).  
 
1.3. Cell motility 
 
1.3.1. Cell motility cycle 
 
Cell motility is an essential cellular process involved in numerous physiological 
events including embryogenesis, wound healing, inflammation and tissue 
regeneration. Moreover, it is a central process for cancer cell invasion and metastasis.  
Cell migration usually occurs in response to a chemoattractant or a growth factor 
present around the cell, a process known as chemotaxis. A great effort in research 
has been directed towards understanding the molecular basis of cell motility in an 
attempt to find novel therapeutic targets that would inhibit tumor growth and 
metastasis (Lauffenburger & Horwitz, 1996).  
Once a signal is detected, a migrating cell enters the cell motility cycle in an 
amoeboid-like manner. This starts with determining the direction of motion towards 
the chemoattractant. Then the cell extends a protrusion, towards the direction of 
motion, by initiating the polymerization of new actin filaments (Bailly, Condeelis, & 
Segall, 1998). The actin-rich protrusion then needs to be stabilized by the formation 
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of adhesions to the cell substratum. This provides anchorage to the cell to transmit a 
mechanical force used to pull its cell body forward towards the direction of motion. 
Simultaneously, the adhesion structures at the rear end of the cell are disassembled 
and the cell retracts its tail and moves forward (Figure 4) (Ananthakrishnan & 
Ehrlicher, 2007; Bailly, Yan, Whitesides, Condeelis, & Segall, 1998; J. S. Condeelis, et 
al., 2001). 
Numerous intracellular proteins are involved in the regulation of the cell motility 
cycle. One of the most important family of proteins regulating this process is the Rho 
family GTPases. Members of this family play a crucial role in the reorganization of 
the actin cytosekeleton (J. Condeelis, 2001; van Golen, 2003).  
 
                                
Figure 4: The cell motility cycle. A migrating cell first protrudes an extension in the 
direction of motion, forms adhesions to stabilize this protrusion, then detaches old 
adhesions at the rear end, and finally complete the cell cycle by retracting its tail and 
pulling its cell body forward. Source: (Childs, 2001).  
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1.3.2. Altered cell motility and cancer 
 
Cell motility is a complex multistep process that integrates multiple intracellular 
signaling and regulatory pathways. Therefore, slight modifications in any step may 
dramatically affect normal cellular functions and result in cellular transformation and 
carcinogenesis. It is known that cell motility is essential for metastasis and without it 
tumors would be easily eradicated and/or surgically removed (Jiang, et al., 2009).  
The acquisition of a motile phenotype is a critical step towards carcinogenesis and 
is required for a cell to gain metastatic competence. Thus, further descriptions of the 
molecular mechanisms regulating cancer cell motility would facilitate the development 
of specific and effective therapeutic treatments against metastasis and tumor cell 
invasion (Jiang, et al., 2009; van Golen, 2003).   
 
1.4. Cell invasion  
 
During cancer cell metastasis, cells emigrate from the primary site of the tumor into 
the bloodstream and are carried along to distant sites where they can extravasate out of 
blood vessels forming secondary neoplastic tissues (Gertler & Condeelis, 2011). To do so, 
cancer cells must penetrate the dense extracellular matrix (ECM) degrading the basement 
membrane and migrate towards blood and lymphatic vessels (Gertler & Condeelis, 2011; 
Kim, Liotta, & Kohn, 1993; Sahai, 2005).  
Cellular invasion is defined as the transition from a primary tumor growth to a 
malignant phenotype. It is a multistep process that involves coordinated and well-
organized intracellular and extracellular communications (Calvo & Sahai, 2011; Kim, et al., 
1993).  
 
1.4.1. ECM degradation 
 
Initially, malignant cells transverse the underlying epithelial basement membrane 
and invade into the interstitial stroma of the extracellular matrix. This requires effective 
proteolysis of the ECM components including type IV collagen, glycoproteins and 
proteoglycans (Kim, et al., 1993). For this reason, cells secrete proteases and/or factors 
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that activate matrix proteases. These include matrix metalloproteinase’s (MMPs), which 
are secreted as inactive pro-enzymes and activated extracellularly.  Plasmin is one the 
factors needed to cleave secreted pro-enzymes and activate them. However, the 
secreted MMPs must overcome the presence of endogenous inhibitors (TIMPs) that 
may impede invasion process. Thus, the balance between active proteases and their 
inhibitors is crucial in determining the invasive phenotype of malignant cells 
(Aznavoorian, Murphy, Stetler-Stevenson, & Liotta, 1993; Gertler & Condeelis, 2011; 
Stetler-Stevenson, Aznavoorian, & Liotta, 1993).   
After successful degradation of the ECM, cells are now free to migrate towards 
the circulatory system. This process is associated with tumor-induced angiogenesis, 
which not only promotes tumor expansion but also allows easy access to vascular 
tissues (Aznavoorian, et al., 1993). Moreover, the process of invasion and metastasis 
involves a complex network of interactions with surrounding host tissues and other 
components of the tumor microenvironment (Calvo & Sahai, 2011) This comprises 
numerous molecular pathways that steer and direct cellular migration (Mareel & 
Constantino, 2011). Finally, to successfully establish neoplastic tissue at distant sites, 
circulating tumor cells must be able to survive host immune system, extravasate out of 
the capillary and ultimately invade and proliferate in the tissue of the secondary site 
(Gertler & Condeelis, 2011; Kim, et al., 1993; Mareel & Constantino, 2011).  
 
1.4.2. Molecular mechanism of invasion 
 
In order to accomplish the successive steps during invasion, tumor cells are 
believed to form F-actin rich membrane protrusions known as invadopodia along 
with matrix metalloproteinase activity to degrade the dense extracellular barriers 
(Bravo-Cordero, et al., 2011). These structures extend vertically into the underlying 
ECM (J. Condeelis & Segall, 2003). Invadopodia are enriched with a network of actin 
filaments, actin binding proteins, matrix proteinases and regulatory proteins involved 
in actin polymerization and remodeling (Yamaguchi, et al., 2005).  
Molecular mechanisms regulating the dynamics of invadopodia include signaling 
proteins such as Arp2/3, cofilin, cortactin and N-WASP, in addition to proteins that 
regulate matrix degradation such as MT1-MMP (Artym, Zhang, Seillier-Moiseiwitsch, 
Yamada, & Mueller, 2006; Yamaguchi, et al., 2005). Cofilin generates free barbed 
ends through the severing of actin filaments, leading to actin nucleation. Severing is 
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needed to expose free barbed ends since most filaments in resting cells are capped 
(Bravo-Cordero, et al., 2011; W. Wang, Eddy, & Condeelis, 2007). Cofilin is 
phosphorylated and inactivated by LIM and TES family kinases, by blocking its 
ability to bind to F-actin (Bravo-Cordero, et al., 2011). Studies have shown that the 
Rho family of small GTPases activate downstream kinase named ROCK that 
phosphorylates and activates LIM kinase (LIMK) (Olson & Sahai, 2009). (Figure 7) 
(Rho GTPases and their effectors are discussed later in details) 
De novo nucleation is another mechanism by which barbed ends can be generated 
and this is mediated by the Arp2/3 complex, which provides a template for actin 
nucleation (Olson & Sahai, 2009). Arp2/3 is activated by the Wiskott-Aldrich 
syndrome protein (WASP) family. The WASP/SCAR/WAVE family of scaffold 
proteins directly bind to Arp2/3 via the VCA domain and are key regulators of actin 
polymerization (Olson & Sahai, 2009; Yamaguchi, et al., 2005).  
Therefore, the regulation of actin dynamics in invadopodia is essential for tumor 
invasion and metastasis.  	  
1.4.3. EMT 
 
It is well known that the epithelial-mesenchymal transition is fundamental for 
tumor progression. Moreover, there is increasing evidence that the process of EMT 
is responsible for the dissemination of primary tumor epithelial cells to secondary 
metastatic sites and their acquisition of malignant phenotype (Thiery, 2002).  
EMT of cancer cells is characterized by a downregulation of epithelial markers 
accompanied by an upregulation of mesenchymal proteins. This is reflected on the 
morphological basis depicted by an elongated polarized shape, pseudopodia 
formation, loss of cell-cell adhesion and increased motility (Morra & Moch, 2011; 
Thiery, 2002). Thus, a transient EMT process is required for cancer cell intravasation 
and dissemination.  
Moreover EMT attenuates the immune response and overcomes additional 
safeguard mechanisms implemented against cancer cells including stimulation of 
apoptotic pathways and/or induction of premature senescence (Nieto, 2011). EMT 
also contributes to conferring resistance to radio/chemotherapy. However, once 
tumor cells reach a secondary site, it is important to revert back to epithelial 
phenotype (MET) in order to colonize and form metastases (Nieto, 2011; Thiery, 
2002). 
	   	  	   15	  
 
 
1.5. Rho family GTPases 
 
Members of the Rho-family GTPases are small GTP-binding proteins (GTPases) 
that range between 20-40 KDa in size. These proteins play a vital role in cancer cell 
motility. All aspects of cellular motility and invasion including cellular polarity, 
cytoskeletal re-organization, and signal transduction pathways are controlled through 
the interplay between the Rho-GTPases (Sahai & Marshall, 2002; Tang, Olufemi, Wang, 
& Nie, 2008).  
Activated Rho proteins can bind effector proteins and modulate cell behavior and 
morphology. Rho GTPases are implicated in cell migration through their ability to 
organize and regulate actin-containing structures. Frequent studies have shown that the 
Rho family GTPases regulate cell motility in breast cancer through their ability to 
mediate the remodeling of actin cytoskeleton as well as translating cellular signals from 
plasma membrane receptors to regulate focal adhesion, cell polarity, vesicular trafficking 
and gene expression (Tang, et al., 2008). Approximately 30% of human tumors possess 
a specific mutation in Ras oncogene leading to its protein level overexpression or 
constitutive activation. In contrast to Ras, no mutation in any of the Rho GTPases has 
been identified in breast cancer. Rather, these GTPases are often either overexpressed 
or hyperactive in breast cancer tissue. The variations in the levels of these Rho proteins 
might directly correlate with the advancement of breast cancer (Etienne-Manneville & 
Hall, 2002; Vega & Ridley, 2008). The three most characterized members of the Rho 
GTPases are Rho, Rac and Cdc42 which were found to be distinct in function from the 
other Rho proteins (Takai, Sasaki, & Matozaki, 2001).  
 
1.5.1. General structure of Rho GTPases  
 
All Rho GTPases have a consensus amino acid sequence at the N-terminal half 
that is responsible for specific interaction with GDP and GTP molecules and for a 
GTPase activity that hydrolyzes bound GTP into GDP and Pi.(Valencia, Chardin, 
Wittinghofer, & Sander, 1991) Four important domains are implicated in the binding 
and hydrolysis of GTP (Johnson, 1999). One of the most important domains is the 
effector or switch I domain, which is required for downstream functions of Rho 
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GTPases (Marshall, 1993).  Rho proteins also have sequences at their COOH termini 
that undergo post-translational modifications with lipids, such as farnesyl, 
geranylgeranyl, palmitoyl and methyl moieties, and that are necessary for proper 
localization in the cell (Magee, et al., 1992). 
 
1.5.2. Rho GTPases as binary switches 
 
Rho GTPases switch between two conformations, a GDP-bound inactive state 
where they are sequestered and kept in the cytoplasm; and an active GTP-bound state 
(Sahai & Marshall, 2002; Vega & Ridley, 2008). Since Rho GTPases control many 
important signal transduction pathways, their activation is tightly regulated in the cell. 
The activity of Rho GTPases is regulated by nucleotide binding and by subcellular 
localization (Wennerberg & Der, 2004).  
In response to a certain signal, replacing the bound GDP with a GTP molecule 
activates Rho GTPases. This induces a conformational change favoring the binding of 
the active Rho protein to downstream effectors. After activation of the effector, the 
GTP molecule is hydrolyzed to GDP rendering the GTPase back to its inactive form 
(Etienne-Manneville & Hall, 2002; Tang, et al., 2008). This constitutes a single cycle of 
activation/inactivation of Rho GTPases 
Rho GTPases mediate the transduction of numerous intracellular signaling 
pathways affecting cell behavior and morphology. Thus, these critical proteins are 
implicated in many essential cellular processes including actin dynamics, gene 
transcription, cell cycle progression, cell adhesion, motility and invasion (Etienne-
Manneville & Hall, 2002; Jaffe & Hall, 2005).   
 
1.5.3. Rho GTPases and their regulation 
 
The switch between active GTP-bound and inactive GDP-bound state is 
regulated by Guanine nucleotide exchange factors (GEFs), GTPase-activating 
proteins (GAPs) and Guanine-nucleotide dissociation inhibitors (GDIs). Figure  5 
illustrates the model of Rho protein regulation. 
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Figure 5: Regulation of Rho family proteins. Guanine nucleotide exchange 
factors (GEFs), GTPase-activating proteins (GAPs) and Guanine-nucleotide 
dissociation inhibitors (GDIs). Source: (Sahai & Marshall, 2002).  
 
 
1.5.3.1 GEFs  
 
These proteins have a Dbl homology (DH) domain and other 
domains such as Src homology 3 (SH3) and pleckstrin homology domain 
(PH). These regulators interact with phospholipids of the cell membrane 
and other proteins modulating the GDP-GTP exchange activity (Tang, 
et al., 2008).  
During nucleotide exchange, the initial dissociation of GDP from 
the inactive form of Rho GTPases is considered the rate-limiting step. 
This reaction is very slow and is stimulated by a guanine nucleotide 
exchange factors (GEFs).  Thus, GEFs activate Rho GTPases by 
mediating the exchange of GDP to GTP (Grise, Bidaud, & Moreau, 
2009; Schmidt & Hall, 2002) 
 
1.5.3.2 GAPs 
 
Rho GTPases are negatively regulated by Rho GTPases activating 
proteins (GAPs). These proteins inhibit Rho GTPases by activating their 
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intrinsic GTPase activity. This leads to the hydrolysis of the bound GTP 
into GDP converting Rho GTPases back to their inactive conformation 
(Moon & Zheng, 2003).  
In addition to activating GTP hydrolysis, GAPs may function as 
effectors of Rho GTPases to mediate other downstream effector 
functions (Grise, et al., 2009; Tang, et al., 2008) 
 
1.5.3.3 GDIs 
 
Guanine nucleotide dissociation inhibitors (GDIs) block both the 
GDP/GTP exchange and the GTP hydrolysis. These proteins prevent the 
dissociation of GDP from the inactive Rho proteins and their interaction 
with downstream effectors. GDIs can also bind to the active GTP-bound 
form preventing their interaction with GAPs. Moreover, GDIs modulate 
the cycling of GTPases between the cell membrane and the cytoplasm. 
Since the activity of Rho GTPases crucially depends on their translocation 
to the cell membrane, GDIs are considered important regulators with the 
ability to sequester GTPases in the cytoplasm by masking their 
hydrophobic region/domains (DerMardirossian & Bokoch, 2005; Garcia-
Mata, Boulter, & Burridge, 2011; Grise, et al., 2009).  
 
1.6. Signaling pathways of Rho GTPases 
 
Rho family GTPases are activated in response to numerous extracellular stimuli 
captured by plasma membrane receptors. Hence, these proteins are involved in translating 
signals to regulate various cellular functions including cytoskeleton re-organization, cell-
cell interaction, proliferation, cell adhesion, polarity, chemotaxis and many others (Figure 
6) (Sahai & Marshall, 2002; Tang, et al., 2008).  
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Figure 6: Signaling of Rho family proteins. Rho GTPases are activated in 
response to upstream signals such as growth factors and mitogens. This results in the 
transformation of GDP-bound Rho proteins to active GTP-bound state. Active 
GTPases in turn bind and activate downstream effectors, consequently translating 
various downstream signals including actin remodeling, cell cycle progression, 
transcription and many others. Source: (Grise, et al., 2009).  
 
1.6.1. Upstream signaling 
 
1.6.1.1. PI3K signaling  
 
As mentioned earlier, Rho GTPase-activating proteins GEFs contain 
the pleckstrin homology (PH) domain, a 100-120 amino acid module that 
has a high binding affinity to phosphoinositides and can affect the catalytic 
DH domain of GEFs (Macias, et al., 1994). Binding to PI(4,5)P2 of the 
plasma membrane favors the interaction between PH domain of GEFs 
and the catalytic DH domain inhibiting its activity. PI3K phosphorylates 
PI(4,5)P2 producing PI(3,4,5)P3 that has high affinity to PH domain, thus 
releasing the DH domain and activating GEFs. In turn, GEFs can 
bind/activate Rho GTPases (Schmidt & Hall, 2002).  
External stimuli such as LPA, PDGF, EGF and insulin have been 
shown to trigger the activation of Rho GTPases in a PI3K dependent 
manner. Treatment of fibroblasts with wortmanin, a PI3K inhibitor, 
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inhibited Rho and Rac mediated membrane ruffling in response to EGF 
(Nobes, Hawkins, Stephens, & Hall, 1995; Tang, et al., 2008). These data 
suggest that PI3K acts upstream of Rho GTPases to stimulate membrane 
ruffling in response to growth factors.  
A well-characterized nucleotide exchanger, Vav, is known to be 
activated by PI3K. Vav is phosphorylated on tyrosine residues in the N-
terminal region by Src and Syk kinases leading to the activation of its 
catalytic activity (Lopez-Lago, Lee, Cruz, Movilla, & Bustelo, 2000) An 
autoinhibitory constraint is imposed by its PH domain. However, when 
bound to PI(3,4,5)P3 produced by PI3K, the PH/DH interaction is 
weakened and this alleviates the inhibition (Bustelo, 2000; Crespo, 
Schuebel, Ostrom, Gutkind, & Bustelo, 1997) 
The PH domain of Son of svenless (Sos) also binds to PIP3 
relieving intramolecular inhibition. Sos is a GEF for both Ras and Rac. It 
forms a complex with a number of adaptor proteins downstream of 
receptor tyrosine kinases (Das, et al., 2000; Scita, et al., 1999).  
Therefore, the activity of Rho GTPases is spatially regulated in 
many cellular functions following the subcellular localization of GEFs. 
PI3K activation plays an essential role in regulating the localization of 
GEFs through the production of PIP3 which binds to the PH domain of 
GEFs. Deletion of the PH domain in many GEFs results in the loss of 
in vitro activity, which can be restored by the addition of a CAAX motif 
that targets the protein to the plasma membane (Whitehead, et al., 1996; 
Whitehead, et al., 1999) 
In addition, many studies in mammary tumors have shown that 
PI3K acts downstream of Rac and Cdc42 (Keely, Westwick, Whitehead, 
Der, & Parise, 1997). These findings suggest that PI3K and Rho 
GTPases are involved in a positive feedback loop that stimulates 
lamellipodia formation during cell motility.  
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                       1.6.1.2. Activation by adhesion  
 
Numerous signaling pathways involving Rho GTPases are activated 
downstream of the cell adhesion to the ECM (DeMali & Burridge, 2003). 
In this respect, the activation of focal adhesion kinase (FAK) leads to the 
phosphorylation and activation of p130cas and paxillin (DeMali & 
Burridge, 2003; Zamir & Geiger, 2001). Phosphorylated p130cas activates 
Rac by forming a complex with adaptor proteins Crk and DOCK180, 
which is a GEF for Rac (Cary, Han, Polte, Hanks, & Guan, 1998; Klemke, 
et al., 1998; Matsuda, et al., 1996). Paxillin also forms a multi-component 
complex with the protein PKL and PIX, the latter being another Rac GEF 
(Bagrodia, Taylor, Jordon, Van Aelst, & Cerione, 1998).  
In addition to activating Rac, FAK also activates p190RhoGAP thus 
leading to the inhibition of RhoA. In many cells, during initial cell 
adhesion, FAK activity stimulates high Rac activity and low RhoA activity 
(O'Connor, Nguyen, & Mercurio, 2000).  
 
1.6.2. Downstream signaling 
 
        1.6.2.1. Rho effectors  
 
Downstream targets of Rho include the serine/threonine kinase 
p160ROCK which is mainly involved in the formation of stress fibers and focal 
adhesions (Struckhoff, Rana, & Worthylake, 2011). ROCK is known to 
phosphorylate myosin light chain (MLC) leading to actin-myosin contractility 
(Grise, et al., 2009; Tang, et al., 2008). At the same time, ROCK inhibits MLC 
dephosphorylation by inhibiting MLC phosphatases via their myosin binding 
subunit (MBS) (Kimura, et al., 1996). However, normal stress fiber formation 
also require the activity the mammalian homolog of diaphanous (mDia), another 
important Rho effector mediating actin nucleation (Alberts, 2001).  
LIMK is another downstream effector of Rho, which phosphorylates the 
actin severing protein cofilin. As mentioned earlier (in section 1.4.2.), cofilin 
function is inhibited upon phosphorylation (Olson & Sahai, 2009).  
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Other Rho effectors include members of the ezrin-radixin-moesin (ERM) 
proteins. These proteins are found to associate with the cell plasma membrane 
where they mediate Rho-dependent actin cytoskeleton remodeling (Figure 7) 
(Takaishi, Sasaki, Kameyama, Tsukita, & Takai, 1995; Tang, et al., 2008).  
 
                    
Figure 7: Downstream effectors of Rho. Explained in text in section 1.6.2.1. 
 
          1.6.2.2. Rac/Cdc42 effectors  
 
Downstream signaling of Cdc42 and Rac include scaffold proteins 
belonging to the WASP/SCAR/WAVE family containing the VCA domain 
(Keely, et al., 1997; Tang, et al., 2008). These are key regulators of actin 
nucleation protein Arp2/3 complex that stimulates actin polymerization at the 
leading edge of the cell (Jaffe & Hall, 2005; Jiang, et al., 2009; Tang, et al., 2008; 
Yamaguchi, et al., 2005).  
Some proteins are target effectors of both Rac and Cdc42. One of these 
proteins is the serine/threonine p21 activating kinase (PAK). PAK isoforms 
have an N-terminal regulatory domain and a C-terminal catalytic domain 
(Manser, Leung, Salihuddin, Zhao, & Lim, 1994). Moreover, all PAK proteins 
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share a common domain responsible for interaction with Rac and Cdc42, 
referred to as Cdc42/Rac interactive binding (CRIB) domain (Burbelo, 
Drechsel, & Hall, 1995; Manser, et al., 1994) Binding of active GTPase disrupts 
the autoinhibitory conformation of PAK and activates its catalytic domain by 
phosphorylation (Manser, et al., 1994). Active PAK phosphorylates MLCK 
thereby inactivating it and inhibiting MLC phosphorylation and contractility 
(Sanders, Matsumura, Bokoch, & de Lanerolle, 1999). PAK is also targeted to 
adhesion complexes regulating focal adhesion turnover (Bokoch, 2003). In 
addition, PAK phosphorylates and activates LIMK (Figure 8) (Edwards, 
Sanders, Bokoch, & Gill, 1999). LIMK is therefore activated through ROCK 
and PAK pathways downstream of Rho and Cdc42/Rac respectively. This 
potentially results in the phosphorylation of cofilin inhibiting its actin-severing 
function and stabilizing actin polymerization at the leading edge of the cell 
(Burridge & Wennerberg, 2004) 	  
 
 
Figure 8: Downstream effectors of Rac and Cdc42. Explained in text in section 
1.6.2.2.  
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1.7. Role of Rho GTPases in cell motility 
 
In general, cell migration can be divided into separate successive steps: determining 
the direction of motion, cell polarization, lamellipodial protrusion, adhesion formation 
followed by cell body contraction and tail retraction (Figure 9) (Lauffenburger & Horwitz, 
1996).  
 
 
             
 
Figure 9: Rho GTPases in cell motility. A migrating cell enters cell motility cycle. 
Cdc42 determines the direction of motion. Rac induces lamellopodial formation at the 
leading edge by stimulating actin polymerization and focal complexes. Rho acts at the 
rear end leading to actin-myosin contractility and tail retraction.  
 
1.7.1. Direction of motion and protrusion formation 
 
The initial step during cell migration is the determination of direction of motion 
by generating membrane protrusions. These protrusions can be either spike-like 
filopodia or larger, broad lamellipodia (Tang, et al., 2008).  
Filopodia are classically regarded as sensors for chemotactic cues required for 
direction sensing during cell migration. These protrusions extend out from the cell 
detecting and transmitting any environmental changes (Arjonen, Kaukonen, & Ivaska, 
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2011; Ridley, 2001). Cdc42 regulates the formation of filopodia by initiating actin 
polymerization through the activation of N-WASP (Nobes & Hall, 1999).  
The lamellipodium is a meshwork of highly branched actin filaments at the cell 
edge (Small, Stradal, Vignal, & Rottner, 2002) The structure of the lamellipodia is 
known to be Rac-dependent involving a number of Rac downstream effectors (Figure 
8) such as severing proteins ADF/cofilin (Van Troys, et al., 2008)and actin binding 
proteins like the Arp2/3 complex that is responsible for actin nucleation and 
branching. As well as the activation of PIP-5 kinase that produces PIP2 inhibiting 
actin-capping proteins. However these effectors are also downstream of Cdc42 (Figure 
8). Consequently, Cdc42 is regarded as a potential regulator that drives Rac-dependent 
lamellipodia (El-Sibai, et al., 2007; Hall, 1998). In addition to its role in actin regulation, 
Cdc42 plays a crucial role in defining cell polarity with respect to the direction of 
motility, through the regulation of the microtubule cytoskeleton (Johnson, 1999) 
 
1.7.2. Adhesion formation 
 
Extended protrusions of migrating cells need to be stabilized by adhering to the 
ECM (J. S. Condeelis, et al., 2001). Cell adhesion to the ECM activates Rac and Cdc42 
(as described in section 1.6.1.2.), which is required for cell spreading (Price, Leng, 
Schwartz, & Bokoch, 1998). It is therefore possible that there is continuous formation 
of new interactions between integrins and the ECM. The speed of cell migration 
depends on the composition of the substratum that dictates the relative levels of active 
Rho, Rac and Cdc42. Thus, a constant crosstalk between integrins and Rac is decisive 
for the cellular response to changing ECM composition (Nobes & Hall, 1999; Price, et 
al., 1998; Ridley, 2001; Tang, et al., 2008).  
Rac stimulates the assembly of small punctate structures known as focal 
complexes that form behind the leading lamellipodium of the cell. However, these 
structures do not transmit adequate contractility during cell motility (Kaverina, 
Krylyshkina, & Small, 2002). Rac induces focal complex formation directly, through 
activating PAK (Figure 8), which in turn interacts with a complex of the exchange 
factor PIX, paxillin and GIT family of proteins. Also, Rac can indirectly contribute to 
the formation of focal complexes through antagonizing Rho activation (Rottner, Hall, 
& Small, 1999; Sander, ten Klooster, van Delft, van der Kammen, & Collard, 1999; 
Tang, et al., 2008). As the cell moves in the direction of motion, focal complexes can 
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either disassemble or mature into larger and more stabilized Rho-dependent structures 
known as focal adhesions (Arjonen, et al., 2011; Wolfenson, Henis, Geiger, & 
Bershadsky, 2009).  
Focal adhesions provide anchorage for the cell thus conferring mechanical 
strength needed for the cell to contract its cell body and slide along the ECM 
(Wolfenson, et al., 2009).  
Therefore, cell migration requires the focal complex/adhesions turn over 
regulated by the interplay between Rac and RhoA. Increasing Rho activation stabilizes 
focal adhesion attachments to the ECM, hence inhibiting cell motility (Cox, Sastry, & 
Huttenlocher, 2001; Sander, et al., 1999) 
 
1.7.3. Cell body contraction and tail retraction 
 
In a migrating cell, adhesion to the ECM alone is not sufficient. Cell body 
contractility and tail retraction are needed for the completion of the cell motility cycle 
(Figure 4).  
Cell body contraction depends on actomyosin contractility, which is directly 
regulated by Rho. Rho acts via ROCK inducing contractility through the 
phoshporylation of MLC (Figure 7). This results in transmission of tension to the sites 
of adhesion. MLC is also regulated by MLC kinase (MLCK), thus it is likely that 
ROCK and MLCK act in concert to control cell contractility (Tang, et al., 2008). In 
addition to the ROCK pathway, RhoA is believed to negatively regulate cofilin leading 
to the inhibition of cell protrusions (El-Sibai, et al., 2008; Worthylake & Burridge, 
2003). Thus, RhoA localizes to the rear of the cell inhibiting protrusions during 
motility.  
Tail retraction is the final step of cell migration (Figure 9). At this point, 
adhesions must disassemble to ensure the completion of the cell motility cycle 
(Palecek, Huttenlocher, Horwitz, & Lauffenburger, 1998). Although the mechanism of 
tail detachment depends on the cell type and the strength of adhesion to the ECM, it is 
known that the reduction in RhoA activity could potentially inhibit retraction through 
reduced actomyosin contractility (Cox, et al., 2001; El-Sibai, et al., 2008; Worthylake & 
Burridge, 2003).  
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Therefore, the continuous interplay between Rho GTPases govern all aspects of 
cell motility including cell polarity, cytoskeleton re-organization, adhesion formation, 
cell contraction and tail retraction (Nobes, et al., 1995; Ridley, 2001) 
 
1.7.4. Crosstalk between Rho GTPases 
 
It was initially believed that Rho, Rac and Cdc42 play a defined role in regulating 
actin and adhesion dynamics during cell motility. However, this model is considered 
too simplistic due to crosstalk between the signaling pathways regulated by Rho 
GTPases (Khalil & El-Sibai, 2012). It was recently shown that RhoA for instance, is 
not only restricted to the generation of contractile force at the rear end of the cell, but 
also coordinates with Rac and Cdc42 at the cell edge in regulating actin cytoskeleton 
(El-Sibai, et al., 2008). Other studies have revealed an inverse relationship between Rho 
and Rac, where activation of Rac leads to the inactivation of Rho and vice versa 
(Sander, et al., 1999). This antagonism is explained in their antagonistic functions in 
cell adhesion (as described in section 1.7.2). Other examples where one family member 
negatively affects the activity of the other is through stimulating a GAP, or positively 
activating another through stimulating a GEF (Burridge & Wennerberg, 2004) 
 
1.7.5. Altered role in cancer  
 
The acquisition of motile and invasive phenotypes is the key component in 
developing metastatic competence. Both of these processes are strictly regulated by 
members of the Rho family GTPases (Sahai & Marshall, 2002). Studies have shown 
that constitutively activated Rho GTPases lead to the transformation of fibroblasts. In 
addition, genetic screening showed that Rho GTPases, particularly RhoA and RhoC, 
are found to be either overexpressed or hyperactive in many tumors including breast 
cancer (Sahai & Marshall, 2002; Tang, et al., 2008). Moreover, overexpression of RhoC 
was associated with 32% of invasive breast cancer and invasive ductal carcinoma 
(Kleer, et al., 2002; van Golen, 2003). In fact, forced expression of Rho proteins 
induced malignant transformation of human mammary epithelial cells resulting in an 
aggressive and highly motile phenotype. In addition, expressing a dominant-negative 
form of Rho inhibited cellular motility (Clark, Golub, Lander, & Hynes, 2000). 
Therefore, aberrant expression of Rho GTPases primarily contributes to cell 
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transformation and tumor development, given their role in the regulation of actin 
polymerization and motility and their interaction with numerous signaling pathways 
(Sahai & Marshall, 2002).  
Dominant inhibitory/activating approaches have been used to describe the role 
of Rho GTPases in primary tumor growth and metastasis. Regulatory proteins GEFs 
and GAPs can cause dysfunctional activation/inhibition of Rho GTPases affecting 
cellular motility, invasion and ultimately metastasis (Bouzahzah, et al., 2001; M. Lin & 
van Golen, 2004). Moreover, as Rho GTPases are highly involved in promoting 
cellular transformation, many downstream effectors could be directly involved in 
tumor formation. For instance, direct inhibition of RhoA, through microinjection of 
C3T, or inhibiting its downstream effector ROCK using Y27632 leads to decreased 
motility and inhibition of focal complex maturation into focal adhesions (El-Sibai, et 
al., 2008).  
There is also evidence that aberrant activation of Rho proteins can contribute to 
prolonged survival and prevent apoptosis. This is because of the ability of Rho 
GTPases to affect CDKs involved in regulating cell cycle progression promoting 
tumor initiation and growth (Tatsuno, Hirai, & Saito, 2000). Cyclin D1 is found to be 
overexpressed in 50% of breast cancers. Rho GTPases correlate to high expression of 
cyclin D1 through the activation of its promoter. Typically, Rac1 affects transcription 
of cyclin D1 through the activation of NF-κB and ATF-2 transcription factors that 
bind and activate cyclin D1 promoter (Guttridge, Albanese, Reuther, Pestell, & 
Baldwin, 1999; Joyce, et al., 1999). Thus, constitutively active forms of Rac1 stimulated 
transformation potential and cell proliferation through cyclin D1 overexpression 
(Joyce, et al., 1999). In addition, RhoA overexpression inhibits p21, a cyclin-dependent 
kinase inhibitor and an important tumor suppressor gene product (Liberto, Cobrinik, 
& Minden, 2002). 
Given their integration in various pathways involved in cancer, Rho GTPase and 
their regulators are considered important therapeutic targets through the inhibition of 
cancer cell proliferation, motility and invasion. Several drugs have been shown to 
abrogate Rho GTPase functions. These drugs could directly target Rho proteins such 
as farsenalytrasferase inhibitors (FTIs) and strongylophorine-26 or could act through 
inhibition of their downstream effectors such as ROCK inhibitor Y-27632 (Du & 
Prendergast, 1999; McHardy, Warabi, Andersen, Roskelley, & Roberge, 2005; Tang, et 
al., 2008).  
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1.8. StarD13 
 
1.8.1. Role as a tumor suppressor  
 
DLC2 gene was first identified by Ching et al. (2003). It is located on position 
13q12.3 and was found to be underexpressed in hepatocellular carcinoma (Ching, et al., 
2003). DLC2 is commonly known as steriodogenic acute regulatory protein-related 
lipid transfer domain-containing protein 13 (StarD13). DLC2 shares 64% homology 
with DLC1, another member of the DLC family (Ullmannova & Popescu, 2006). 
StarD13 has an N-terminal SAM motif and a C-terminal START domain. It also 
harbors a RhoGAP domain, which is important to its function (Figure 10) (Ching, et 
al., 2003; Thorsell, et al., 2011; Ullmannova & Popescu, 2006). Overexpression of 
StarD13 was found to associate with significant decrease in cell growth and 
proliferation (Ching, et al., 2003). Moreover, DLC1, a closely related protein is found 
to be underexpressed in many types of cancer including lung, prostate, kidney, colon, 
breast, uterus, and stomach (Liao & Lo, 2008). This data suggests a potential role of 
StarD13 as a tumor suppressor (El-Sitt, et al., 2012) 
 
 
Figure 10: StarD13 structural domains. StarD13 harbors an N-terminal SAM domain 
followed by GTPase regulatory GAP domain and a C-terminal START domain. Source: 
(Thorsell, et al., 2011).  
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1.8.2. StarD13 activity and localization 
 
StarD13 specifically inhibits RhoA and Cdc42. This leads to the inhibition of the 
Rho-dependent actin stress fibers formation (Ching, et al., 2003). Moreover, START 
domain present at the N-terminus of StarD13 is important for targeting it to the 
mitochondria suggesting a possible role in the regulation of the mitochondrial 
membrane permeability and activation of apoptotic pathways (Ng, et al., 2006).  In 
addition, studies on truncated mutants revealed its intracellular localization to focal 
adhesions by the presence of focal adhesion targeting domain (FAT) at its N-terminal 
portion. The FAT domain interacts with tensin2, a component of focal adhesions 
(Kawai, et al., 2009).  
In addition, negative correlation was observed between StarD13 and RhoA in a 
RhoGAP manner. Thus, StarD13 was found to inhibit the function of RhoA through 
inhibiting Rho-mediated assembly of actin stress fibers (Ching, et al., 2003) 
Taken together, it is likely that StarD13 is localized to focal adhesions of the cell 
through its N-terminal FAT domain, where it regulates the activity of RhoA, a process 
strictly correlated to cellular motility.  
 
1.9. Purpose of the study 
 
In this study we aimed at characterizing StarD13 in breast cancer in terms of its level 
of expression and its role in cellular proliferation, migration and invasion.  
We first aimed to determine the level of expression of StarD13 in patient tissues 
representing different grades of breast cancer compared to normal tissues.  Then, we 
wanted to study the effect on cellular proliferation, viability and cell cycle progression 
upon manipulating the level of StarD13 expression.  
Next, we investigated its RhoGAP activity and localization in breast cancer cells.  We 
then opted to determine the role of RhoA and StarD13 in cellular migration.  
Furthermore, we aimed at investigating the role of StarD13 and RhoA in the dynamics of 
cellular adhesion. And finally, we wanted to determine its effect on cell invasion.  
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Chapter II 
MATERIALS & METHODS 
 
2.1. Cell Culture 
 
Human breast cancer cell lines (MCF-7 and MDA-MB231) obtained from ATCC, 
were cultured in DMEM medium supplemented with 10% FBS and 100U 
penicillin/streptomycin at 37°C and 5% CO2 in a humidified chamber.  
 
2.2. Antibodies and reagents 
 
Goat polyclonal anti-StarD13 antibody was obtained from Santa Cruz Biotechnology. 
Mouse monoclonal anti-RhoA, mouse monoclonal anti-Rac1, and mouse monoclonal 
anti-paxillin antibodies were purchased from Upstate biotechnology, Lake Placid, NY. 
Anti-goat and anti-mouse HRP-conjugated secondary antibodies were obtained from 
Promega. Fluorescent secondary antibodies (AlexaFluor 488) were obtained from 
Invitrogen. To visualize the actin cytoskeleton, cells were stained with Rhodamine 
phalloidin (Invitrogen). DAPI was also used to stain nuclei. 
2.3. Cell transfection with siRNA 
 
Goat FlexiTube siRNA for StarD13, RhoA, and Rac1 were obtained from Qiagen. 
The siRNAs used had the following target sequences: StarD13: 5’-
CCCGCAATACGCTCAGTTATA-3’, RhoA: 5’-TTCGGAATGATGAGCACACAA-3’, 
and Rac1: 5’-ATGCATTTCCTGGAGAATATA-3’. The cells were transfected with the 
siRNA at a final concentration of 10 nM using HiPerfect (Qiagen) as described by the 
manufacturer. Control cells were transfected with siRNA sequences targeting GL2 
Luciferase (Qiagen). After 72 hours, protein levels in total cell lysates were analyzed by 
western blotting using the appropriate antibodies or the effect of the corresponding 
knockdown was assayed. 
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2.4. Cell transfection with vectors 
 
Cells were transfected with 5 µg GFP-StarD13, Dominant active RhoA, or control 
empty control vectors using Lipfectamine LTX with Plus reagent (Invitrogen) as 
described by the manufacturer. Cells were incubated with the transfection complexes for 4 
hours then refed with DMEM supplied with 30% FBS. The experiments were carried on 
24 hours following transfection.  
The GFP-StarD13 and the RhoA constructs were generous gifts from respectively 
Dr. Hitoshi Yagisawa from the University of Hyogo, Japan and Dr. Hideki Yamaguchi 
from the Albert Einstein College of Medicine, New York, USA.  
The constructs were transformed into One Shot TOP10 chemically competent E. 
Coli (Invitrogen), which were grown on a selective medium containing the appropriate 
antibiotic. The vectors were then extracted using MaxiPrep plasmid extraction kit from 
Qiagen. 
2.5. Western blotting 
 
Cell lysates were prepared by scraping the cells in a sample buffer consisted of 4% 
SDS, 10% β-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125 M 
Tris-HCl at a pH of 6.8. The resulting lysates were boiled for 5 minutes. Protein samples 
were separated by SDS-PAGE on 8% (for StarD13) or 15% (for RhoA and Rac) gels and 
transferred to PVDF membranes overnight at 30V. The membranes were then blocked 
with 5% non-fat dry milk in PBS containing 0.1% Tween-20 for 1 hour at room 
temperature and incubated with primary antibody at a concentration of 1:100 for 2 hours 
at room temperature. After the incubation with the primary antibody, the membranes 
were washed and incubated with secondary antibody at a concentration of 1:1000 for 1 
hour at room temperature. The membranes were then washed, and the bands visualized 
by treating the membranes with western blotting chemiluminescent reagent ECL (GE 
Healthcare). The results were obtained on an X-ray film (Agfa Healthcare). The levels of 
protein expression were compared by densitometry using the ImageJ software.  
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2.6. RT-PCR 
 
Cells were grown in 6-well plate at density of 1x106 cells/ml and were transfected 
by either control or StarD13 siRNA for 72hrs.  Total RNA was extracted performed 
RNeasy extraction kit (Qiagen) according to manufacturer’s instruction.  Reverse 
transcriptase polymerase chain reaction (RT-PCR) was used to amplify RNA of 
StarD13.  2µg of RNA was converted to cDNA using the OneStep RT-PCR kit 
(Qiagen) as described by the manufacturer. Briefly, gene-specific primers designed to 
detect cDNA were obtained from TIB-MolBiol with the following sequences: Forward: 
5'-AGCCCCTGCCTCAAAGTATT-3', Reverse: 5'-AGCCCCTGCCTCAAAGTATT-
3'. β-actin was used as a control with primers obtained from Sigma-Aldrich having the 
following sequences: Forward: 5’-ATGAAGATCCTGACCGAGCGT-3’, Reverse: 5’-
AACGCAGCTCAGTAACAGT-CCG-3’. Primers were used at a final concentration of 
0.6µM. Primers were added to 5X Qiagen OneStep RT-PCR buffer providing a final 
concentration of 2.5mM MgCl2 in the reaction mix. A final concentration of 400µM of 
each dNTP was added along with 2.0µl/reaction of enzyme mix. Final mastermix 
volume was adjusted to 50µl using RNase-free water. Thermal cycler conditions, for 
both reverse transcription and PCR, was programmed as follows: reverse transcription 
at 50oC for 30min, initial PCR activation step at 95oC for 15min, followed by 25 cycles 
of denaturation at 94oC for 1min, annealing at 52oC for 1min and extension at 72 oC for 
1min followed by a final extension step at 72 oC for 10min. 10µl of the PCR products 
were run on 0.8% agarose gel stained with ethidium bromide at 100V for 30min. The 
resulting bands were visualized under UV light and photographed. β-actin was used as a 
loading control.  
 
2.7. Antigen retrieval and immunohistochemistry 
 
Human breast cancer tissues different grades were provided by Dr. Selim Nasser 
from Clemenceau Medical Center (CMC), Beirut. Tissue blocks were paraffin embedded 
and sectioned to 8 µm sections using a tissue microtome. Sections were deparaffinized in 
two changes of xylene 5min each then hydrated in two changes of 95% alcohol 2min each 
followed by 2 changes of 50% alcohol 2min each. Antigen retrieval was then performed in 
pre-heated Citra Plus (Biogenex) solution. Tissues were then fixed with 4% 
paraformaldehyde for 10 minutes, and permeabilized with 0.5% Triton-X100 for 10 
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minutes. To decrease background fluorescence, tissues were rinsed with 0.1 M glycine 
then incubated with 0.1 M glycine for 10 minutes. For blocking, tissues were incubated 4 
times with 1% BSA, 1% FBS in PBS for 5 minutes. Samples were stained with StarD13 
primary antibody for 2 hours and with a fluorophore-conjugated secondary antibody for 2 
hours. Tissue fluorescent images were taken using a 10X objective on a fluorescent 
microscope. For image analysis, all digital images were imported in image J software 
(National Institutes of Health, MA). The total fluorescence intensity of a fixed area from 
at least 10 different frames from each tissue was determined.  
2.8. Trypan blue exclusion method  
 
Cells were grown in 24 well plates (growth area: 2cm2) at a density of 2x106 
cells/ml. Depending on the experiment, cells were transfected with either StarD13 
siRNA or GFP-StarD13 construct.  Following treatment period, the supernatant from 
each well was collected, cells were washed with PBS, and the PBS washes were added to 
the supernatant of each well. Cells were then trypsinized and collected separately from 
the well contents and PBS. 20µl from each collection tube was mixed with 20µl of 
Trypan Blue. 10µl of this mixture was placed in a counting chamber under the 
microscope, and the number of living and dead cells was recorded accordingly. For each 
well, two countings were done separately, PBS washes/well supernatant and trypsinized 
cells.  Under the microscope, dead cells appear blue, since they are permeable to Trypan 
Blue, while viable cells exclude the stain and thus appear bright.  The percentage of dead 
cells was reported. 
2.9. Cell proliferation reagent (WST-1)  
 
Cells were seeded in 96 well plates (growth area: 0.6 cm2) at a concentration of 
1x106 cells/ml. Depending on the experiment, cells were transfected with either 
StarD13 siRNA or GFP-StarD13 construct with appropriate controls. Following 
treatment period, 10 µl of Cell Proliferation Reagent (WST-1; Roche, Germany) was 
added to each well. The plates were incubated at in a humidified incubator (37°C) in 
95% air and 5% CO2 for 2 hours. WST-1 is a tetrazolium salt that on contact with 
metabolically active cells is cleaved to produce formazan dye by mitochondrial 
dehydrogenases. Quantitation of formazan is done colorimetrically at 450 nm. The 
absorbance of the each blank well was subtracted from the corresponding sample well. 
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The results were normalized to the corresponding controls, and the percent of cell 
proliferation was reported. 
2.10. Immunostaining  
 
The cells were plated on cover slips, and the appropriate treatment was applied. 
Cells were fixed with 4% paraformaldehyde for 10 minutes, and permeabilized with 
0.5% Triton-X100 for 10 minutes. To decrease background fluorescence, cells were 
rinsed with 0.1 M glycine then incubated with 0.1 M glycine for 10 minutes. For 
blocking, cells were incubated 4 times with 1% BSA, 1% FBS in PBS for 5 minutes. 
Samples were stained with primary antibodies for 2 hours and with fluorophore-
conjugated secondary antibodies for 2 hours. Fluorescent images were taken using a 
60X objective on a fluorescent microscope. 
 
2.11. Pull down assay 
 
Cells were either transfected with GFP-StarD13 construct or an empty GFP 
construct as a control. Following treatment period, cells were lysed and the pull-down 
assay performed using the RhoA/Rac1/Cdc42 Activation Assay Combo Kit (Cell 
BioLabs) following the manufacturer’s instructions. Briefly, cell lysates were incubated 
with GST-RBD (for RhoA) or GST-PAK (for Rac1/Cdc42) for 1 hour at 4 °C with 
gentle agitation. Then, the samples were centrifuged, and the pellet washed for several 
times. After the last wash, the pellets were resuspended with sample buffer and boiled for 
5 minutes. GTP-RhoA and GTP-Rac1/Cdc42 were detected by western blotting using 
anti-RhoA, anti-Rac1 and anti-Cdc42 antibodies provided in the kit. Total proteins were 
collected prior to the incubation with GST beads and used as a loading control.  
2.12. Wound healing assay 
 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. After wounding, the cells were washed twice with PBS 
to remove debris and new medium was added. Phase-contrast images of the wounded 
area were taken at 0 and 24 hours after wounding. Wound widths were measured at 11 
different points for each wound, and the average rate of wound closure was calculated in 
µm/hr. 
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2.13. Motility assay 
 
For motility analysis, images of cells moving randomly in serum were collected every 
60 seconds for 2 hours using a 20X objective. During imaging, the temperature was 
controlled using a Nikon heating stage which was set at 37 °C. The medium was buffered 
using HEPES and overlayed with mineral oil. The speed of cell movement was quantified 
using the ROI tracker plugin in the ImageJ software, which was used to calculate the total 
distance travelled by individual cells. The speed is then calculated by dividing this distance 
by the time (120 minutes) and reported in µm/min. The speed of at least 15 cells for each 
condition was calculated. The net distance travelled by the cell was calculated by 
measuring the distance travelled between the first and the last frames.  
2.14. Adhesion assay 
 
96-well plates were coated with collagen using Collagen Solution, Type I from rat tail 
(Sigma) overnight at 37 °C then washed with washing buffer (0.1% BSA in DMEM). The 
plates were then blocked with 0.5% BSA in DMEM at 37 °C in a CO2 incubator for 1 
hour. This was followed by washing the plates and chilling them on ice. Meanwhile, the 
cells were trypsinized and counted to 4x105 cell/ml. 50 µl of cells were added in each well 
and incubated at 37°C in a CO2 incubator for 30 minutes. The plates were then shaken 
and washed 3 times. Cells were then fixed with 4% paraformaldehyde at room 
temperature for 10 minutes, washed, and stained with crystal violet (5 mg/ml in 2% 
ethanol) for 10 minutes. Following the staining with crystal violet, the plates were washed 
extensively with water, and left to dry completely. Crystal violet was solubilized by 
incubating the cells with 2% SDS for 30 minutes. The absorption of the plates was read at 
550 µm using a plate reader.  
2.15. Invasion assay 
 
Cells were transfected with either control or StarD13 siRNAs and invasion assay was 
performed 48hrs following treatment period using the collagen-based invasion assay 
(Millipore) according to manufacturer’s instructions. Briefly, 24hrs prior to assay, cells 
were starved with serum free medium. Cells were harvested, centrifuged and then 
resuspended in quenching medium (without serum). Cells were then brought to a 
	   	  	   37	  
concentration of 1x106 cells/ml. In the meantime, inserts were prewarmed with 300µl of 
serum free medium for 30min at room temperature. After rehydration, 250µl of media 
was removed from inserts and 250µl of cell suspension was added. Inserts were then 
placed in a 24-well plate, and 500µl of complete media (with 10% serum) was added to 
the lower wells. Plates were incubated for 24hrs at 37oC in a CO2 incubator. Following 
incubation period, inserts were stained for 20min at room temperature with 400µl of cell 
stain provided with the kit. Stain was then extracted with extraction buffer (also provided). 
100ul of extracted stain was then transferred to a 96-well plate suitable for colorimetric 
measurement using a plate reader. Optical Density was then measured at 560µm.  
 
2.16. Statistical analysis 
 
All the results reported represent average values from three independent 
experiments. All error estimates are given as ± SEM. The p-values were calculated by t-
tests or chi-square tests depending on the experiment using the VassarStats: Website for 
Statistical Computation (http://vassarstats.net/).    
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Chapter III 
RESULTS 
 
3.1. Level of expression of StarD13 in breast cancer  
 
Before studying the role of StarD13 in breast cancer cell, we first wanted to 
investigate its level of expression pattern in human breast cancer tissues. For this, breast 
cancer tissue sections were obtained from patients representing different grades.  We 
then performed immunohistochemistry using an anti-StarD13 antibody (Figure 11A). 
The mean fluorescent intensity was then measured using ImageJ software. StarD13 
showed a high expression level in non-invasive in situ carcinoma. Then, its level of 
expression decreased in grades I and II; however, as we moved on to higher grades of 
the tumor, StarD13 showed a significant increase in its level of expression (Figure 11B).   
    
Figure 11: StarD13 expression levels in different grades of breast cancer. A) 
Representative fluorescent micrographs of formalin-fixed breast caner tissues were 
paraffin embedded and sectioned and then immunostained with anti-StarD113 
antibody: in situ (upper left), grade I (upper right), grade II (lower left) and grade III 
(lower right). B) Quantitation of the immunohistochemistry in A. The mean fluorescent 
intensity/pixel was measured and expressed to the corresponding tissues. Data are the 
mean -/+ SEM from 3 different experiments (with 5 tissues each). *p<0.0001, 
**p<0.04.  
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3.2. StarD13 knockdown increases breast cancer cell viability 
 
Next we wanted to investigate the role of StarD13 on cellular proliferation and 
viability. For this reason StarD13 was knocked down using small interfering siRNA. The 
resulting inhibition in the level of StarD13 was determined using western blot and RT-
PCR in cells transfected with StarD13 siRNA as compared to control cells transfected 
with non-specific siRNA (Figure 12A). β-actin was used as a loading control. StarD13 
knockdown resulted in a 40% decrease of dead cells as determined by trypan blue 
exclusion method (Figure 12B). Similarly, this was reflected in an increase of 15% in cell 
proliferation in cells transfected with StarD13 siRNA as opposed to control cells (Figure 
12C) as determined using Wst-1 reagent.  
 
 
 
Figure 12: StarD13 under-expression increases cell viability. Cells were transfected 
with luciferase control siRNA or with StarD13 siRNA for 72 hours. A) The cells were 
lyzed and immunoblotted by western blot analysis for StarD13 (left upper gel) or for 
actin (left lower gel) for loading control. RT-PCR was also performed to detect StarD13 
levels using StarD13 primer (right upper gel) and actin as loading control (right lower 
gel) B) % of dead cells was determined using Trypan blue, results are shown as percent 
of total number of cells. C) Cell proliferation was determined using WST-1 reagent. Cell 
viability of siRNA-transfected cells was expressed as fold increase from control 
(luciferase-transfected). Data are the mean -/+ SEM from 3 different experiments.  
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3.3. StarD13 over-expression decreases breast cancer cell viability 
 
Cells were transfected with a GFP-StarD13 construct and the resulting cell viability 
was determined as compared to cells transfected with GFP vector alone. Cells 
overexpressing StarD13 showed a drastic increase in the percentage of dead cells as 
compared to control cells as determined using Trypan blue (Figure 13A). On the other 
hand, there was a dramatic decrease in cellular proliferation as determined using the WST-
1 reagent (Figure 13B).  
 
 
 
 
Figure 13: StarD13 over-expression decreases cell viability. Cells were transfected 
with GFP-StarD13 or GFP alone as control for 24 hours. A) The percentage of dead 
cells showed an increase of 50% as determined using Trypan blue. B) Cell proliferation 
of dramatically decreased in cells transfected cells with GFP-StarD13 construct as 
opposed to control cells. Data are the mean -/+ SEM from 3 different experiments.  
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3.4. StarD13 knockdown downregulates tumor suppressors p53 and 
p21 
 
In an attempt to find the mechanism by which StarD13 knockdown is increasing 
cellular proliferation, we immunoblotted for two important tumor suppressors p21 and 
p53. Cells were transfected with a StarD13 siRNA for 72 hours. Cells were lysed and total 
proteins extracted. Immunoblotting was then performed using anti-p21 and anti-p53 
antibodies. Results show a decrease in protein expression levels of both p21 and p53 upon 
knocking down StarD13 (Figure 14). 
 
    
 
 
Figure 14: StarD13 knockdown down-regulates tumor suppressors p53 and p21. 
Cells were transfected with either luciferase control siRNA or with StarD13 siRNA for 
72 hours. Cells were then lysed and immunoblotted by western blot analysis using anti-
p21 (upper gel) or anti-p53 (middle gel) antibodies. Actin was used as a control (lower 
gel).  
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3.5. Role of StarD13 in breast cancer cells 
 
3.5.1. StarD13 localizes to focal adhesions 
 
As described previously, StarD13 localizes to focal adhesions in HeLa cells (Kawai, et 
al., 2009). To investigate the localization of StarD13 in cells, we transfected cells with 
GFP-StarD13 vector and detected its localization by fluorescence microscopy. Also, cells 
were fixed and immunostained using a fluorescent anti-StarD13 antibody (Figure 15)  
 
3.5.2. StarD13 is a GAP for RhoA and Cdc42 
 
StarD13 was also described to act as a GAP for RhoA and Cdc42 but not for Rac 
(Ching, et al., 2003). Hence, we were interested in determining the effect of the over-
expression of StarD13 on the activation of these Rho GTPases in breast cancer cells. 
For this reason, a pull-down assay was performed to detect the level of activation of 
RhoA, Cdc42 and Rac1 in cells transfected with the GFP-StarD13 vector and compare 
it to the level of activation in control cells transfected with an empty vector. The results 
showed a 5-fold decrease in RhoA activation and a 2.5-fold decrease in the activity of 
Cdc42 in cells over-expressing StarD13 as compared to control cells (Figure 16A and 
B). However there was a relative increase in the activity of Rac1 (Data not shown). 
 
                                  
                       
 
Figure 15: StarD13 localizes to focal adhesions. Cells were transfected with GFP-
StarD13 (middle panel) or GFP alone (left panel). Also cells were fixed and 
immunostained using anti-StarD13 antibody (right panel). Micrographs shown were 
imaged using a 60x objective.  
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Figure 16: StardD13 is a specific GAP for Rho and Cdc42. A) Cells were transfected 
with either GFP alone (right lanes) or with GFP-StarD13 (left lanes). The cells were 
then lyzed and incubated with GST-RBD (Rhotekin binding domain) (upper pannels), 
or with GST-CRIB (Cdc42 and Rac interactive binding domain) (lower panels) to pull 
down active Rho and Cdc42 respectively. The samples were then blotted with Rho, and 
Cdc42 antibodies. The lower gels in each panel are western blots for the total cell lysates 
for loading control. B) The bands from the active RhoA and Cdc42 gels were 
quantitated using ImageJ and normalized to the amount of total proteins.  
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3.6. RhoA knockdown inhibits cell motility 
 
After establishing that StarD13 localizes to focal adhesions of the cells and acts as a 
RhoGAP, we wanted to investigate the role of RhoA in breast cancer cell motility. For 
this purpose, RhoA was knocked down using a specific siRNA. The resulting expression 
level was detected by western blot in cells transfected with RhoA siRNA as compared to 
control cells transfected with non-specific siRNA (Figure 17A).  The effect of RhoA 
knockdown was determined by wound healing assay and the cell speed was also assessed 
using time-lapse motility assay. Results showed a decrease of nearly three-folds in the rate 
of wound closure in cells transfected with RhoA siRNA (5.2 µm/hr) as compared to 
control cells (14.8 µm/hr) (Figure 17B and C). This was also reflected by a decrease in 
the average cell speed determined by time-lapse assay, from 0.41 µm/min in controls to 
0.16 µm/min (Figure 18A and B; supplemental movie S1).  
 
 
Figure 17: RhoA is required for cell motility-1. Cells were transfected with luciferase 
control siRNA or with RhoA siRNA for 72 hours. A) The cells were lyzed and 
immunoblotted by western blot analysis for RhoA (upper gel) or for actin (lower gel) 
for loading control. B) The luciferase siRNA-transfected and RhoA siRNA-transfected 
cells were grown in a monolayer then wounded and left to recover the wound then 
imaged at the same frame after 16 hours (lower micrographs). C) Quantitation for B). 
Wound widths were measured at 11 different points for each wound, and the average rate 
of wound closure for the luciferase and the Rho siRNA-transfected cells was calculated in 
µm/hr. Data are the mean -/+ SEM from 3 wound closure assays. The results had 
borderline significance with p<0.05. 
 
	   	  	   45	  
 
Figure 18: RhoA is required for cell motility-2. Cells were transfected with luciferase 
control siRNA or with RhoA siRNA for 72 hours. A) The net paths of projected 120 
frames from 2 hour long time lapse movies of cells undergoing random motility in 
serum (different colors represent different cells) B) Quantitation of the cell speed from 
A) expressed in µm/min. Data are the mean -/+ SEM from 20 cells. The results were 
significant with p<0.001. 
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3.7. Role of StarD13 in cell motility  
 
After establishing that StarD13 localized to focal adhesions where it has a GAP 
activity to Rho and Cdc42, we next wanted to investigate its role in cellular motility. For 
this reason, StarD13 was knocked down using siRNA oligonucleotides. The knockdown 
was confirmed by western blot and RT-PCR (Figure 12A). Results show that StarD13 
knockdown decreased the rate of wound closure from 14 µm/hr to 7 µm/hr (Figure 19A 
and B). Furthermore, StarD13 knockdown significantly decreased the average speed of 
individual cells from 0.41 µm/min to 0.20 µm/min (Figure 19B and C). Altogether these 
results show that the knockdown of StarD13 inhibits breast cancer cell motility.  
Looking at the morphology, cells were observed be stuck and not able to detach their tail 
in order to move forward (Figure 20A; supplemental movie S2) 
 
 
Figure 19: StarD13 is required for cell motility-1. Cells were transfected with 
luciferase control siRNA or with StarD13 siRNA for 72 hours. Cells were grown in a 
monolayer then wounded and left to recover the wound then imaged at the same frame after 16 
hours (lower micrographs). B) Quantitation for A). Wound widths were measured at 11 different 
points for each wound, and the average rate of wound closure for the luciferase and the StarD13 
siRNA-transfected cells was calculated in µm/hr. Data are the mean -/+ SEM from 3 wound 
closure assays. The results were significance with p<0.01. 
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Figure 20: StarD13 is required for cell motility-2. Cells were transfected with 
luciferase control siRNA or with StarD13 siRNA for 72 hours. A) Montage of time-
lapse movie (60 sec apart) showing StarD13 siRNA-transfected cells undergoing 
random motility in serum (MCF-7: upper panel, and MDAs: lower panel). B) The net 
paths of projected 120 frames from 2 hour long time lapse movies of cells undergoing 
random motility in serum (different colors represent different cells) C) Quantitation of 
the cell speed from A) expressed in µm/min. Data are the mean -/+ SEM from 20 cells. 
The results were significant with p<0.001. 
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3.8. Dominant active RhoA inhibits cell motility 
 
After showing that RhoA knockdown inhibits cell motility and that StarD13 
knockdown, where Rho is kept active, also inhibits cell motility it was of great interest to 
us to determine the effect of overexpressing a constitutively active form of RhoA. Thus, 
similar to StarD13 knockdown, dominant active RhoA suppressed cellular motility. This 
was observed through wound healing assay where the rate of wound closure was 
decreased from 12.3 µm/hr to 3.4 µm/hr (Figure 21).  
 
 
 
Figure 21: Constitutively active RhoA inhibits cell motility. Cells were left 
untransfected or transfected with a dominant active RhoA construct (RhoA DA). A) 
Cells were grown in a monolayer then wounded and left to recover the wound then 
imaged at the same frame after 16 hours (lower micrographs). B) Quantitation for A). 
Wound widths were measured at 11 different points for each wound, and the average rate 
of wound closure was calculated in µm/hr. Data are the mean -/+ SEM from 3 wound 
closure movies. The results were significant with p<0.001. 
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3.9. Dynamics of focal adhesions 
 
After establishing the role of StarD13 in cell motility, we were interested in looking 
directly at focal adhesion. For this reason, we immunostained for Paxillin, a component of 
both focal complexes and focal adhesions (Nobes & Hall, 1999) using anti-paxillin 
antibody.  
 
3.9.1. Rac is needed for the formation of focal complexes 
 
Rac1 was knocked down using specific siRNA and stained for actin, nucleus and 
paxiliin. When observed under a fluorescent microscope, neither focal 
complexes nor focal adhesions were visible at the cell edge (Figure 22).  
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Figure 22: Rac is needed for formation of focal complexes. A) Representative 
micrographs of (MCF-7) cells that were transfected with either luciferase (left) or Rac 
siRNA (right) fixed and immunostained with anti-paxillin antibody. Cells were imaged 
using a 60x objective. B) Quantitation for A) represented as percentage of focal 
adhesions and focal complexes in control cells. Data are the mean -/+ SEM from 15 
cells. Results showed borderline significance with p<0.04.  
 
 
3.9.2. RhoA is needed for the maturation of focal adhesions 
 
It was previously reported that RhoA is needed for the maturation of focal 
complexes into focal adhesions (Arjonen, et al., 2011; Wolfenson, et al., 2009). 
Thus, to verify this role in our system, RhoA was silenced it in breast cancer cells 
and stained for paxillin. Indeed, focal adhesions were less prevalent instead small 
punctate structures were highly present representing immature focal complexes 
(Figure 23A). This was reflected in a reduction of the percentage of focal 
adhesions from 46.3% in control cells to 20.9% in cells with RhoA knockdown. 
On the contrary, the percentage of focal complexes increased from 53.7% in 
control cells to 79.1% in cells transfected with RhoA siRNA (Figure 23B).  
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Figure 23: RhoA is needed for the maturation of focal complexes. A) 
Representative micrographs of (MCF-7) cells that were transfected with either luciferase 
(left) or RhoA siRNA (right) fixed and immunostained with anti-paxillin antibody. Cells 
were imaged using a 60x objective. B) Quantitation of A) represented as percentage of 
focal adhesions and focal complexes in cells with RhoA knockdown. Data are the mean 
-/+ SEM from 15 cells. The results were significant with p<0.0001. 
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3.9.3. StarD13 knockdown stabilizes focal adhesions 
 
To investigate the effect of StarD13 on the dynamics of focal adhesions, we 
then transfected cells with StarD13 siRNA and stained for paxillin. Focal 
adhesions in these cells were more pronounced and more stable especially at the 
cell edges as compared to control cells (Figure 24A). Qunatitatively, 70.1% of 
adhesion structures were focal adhesions as opposed to 29.9% representing focal 
complexes (Figure 24B).  
 
 
Figure 24: StarD13 knoockdown stabilizes focal adhesions. A) Representative 
micrographs of (MCF-7) cells that were transfected with StarD13 siRNA fixed and 
immunostained with anti-paxillin antibody. Cells were imaged using a 60x objective. B) 
Quantitation of A) represented as percentage of focal adhesions and focal complexes in 
cells with StarD13 knockdown. Data are the mean -/+ SEM from 15 cells. The results 
were significant with p<0.0001. 
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3.9.4. RhoDA mimics StarD13 phenotype stabilizing focal adhesions 
In order to verify our hypothesis, similar to StarD13 knockdown, 
transfecting the cells with a dominant active form of RhoA lead to the 
stabilization of focal adhesions (Figure 25A). This was also reflected by a 
difference of more than 50% between the amounts of focal adhesions and focal 
complexes. The majority of adhesion structures in cells over-expressing a 
constitutively active RhoA were actually focal adhesions representing 77% as 
compared to 23% representing focal complexes (Figure 25B).  
 
Figure 25: RhoDA mimics StarD13 knockdown phenotype A) Representative 
micrographs of (MCF-7) cells that were transfected with RhoA-DA contruct fixed and 
immunostained with anti-paxillin antibody. Cells were imaged using a 60x objective. B) 
Quantitation of A) represented as percentage of focal adhesions and focal complexes in 
cells with RhoA-DA knockdown. Data are the mean -/+ SEM from 15 cells. The 
results were significant with p<0.0001. 
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3.10. StarD13 knockdown increases cellular adhesion to collagen 
 
Since it was shown to increase focal adhesion formation and stabilization, we 
next aimed at studying the effect of StarD13 knockdown on the adhesion of breast 
cancer cells to collagen. The results showed more than two-fold increase in the 
adhesion of cells with the StarD13 knockdown as compared to control cells (Figure 
26A and B).  
 
 
 
Figure 26: StarD13 knockdown increases cellular adhesion to collagen. A) 
Representative micrographs of cells fixed and stained with crystal violet to detect 
adhesion (as described in methods). B) Quantitation of A) Crystal violet was solubilized 
and the absorption of the plates was read at 550 µm using an ELISA plate reader. Data is 
measured in arbitrary units and normalized to the luciferase control. Data are the mean -
/+ SEM from 3 experiments. The results were significant with p<0.001. 
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3.11. StarD13 knockdown increases cellular invasion 
 
After establishing the role of StarD13 in 2D cell migration, we were interested in 
determining its role in 3D cell invasion. For this reason, we performed an in vitro 
collagen-based invasion assay using FBS as a chemoattractant. A chamber with 
serum free media in both wells was used as negative control. To our surprise, unlike 
its effect in 2D, there was nearly a half-fold increase in cell invasion in cells with 
StarD13 knockdown as compared to control cells (Figure 27A and B).  
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Figure 27: StarD13 knockdown increases cellular invasion. A) Representative 
micrographs of invaded cells on the bottom side of the membrane stained with cell stain 
according to assay instructions. Cells with StarD13 knockdown and control cells were 
allowed to invade towards 10% FBS for 24hrs. 1x106 cells/ml were used in each assay. B) 
Cell stain was extracted and colorimetric measurements were taken at 560 µm. Data is 
measured in arbitrary units. Data are the mean -/+ SEM from 3 experiments. The results 
were significant with p<0.02.  
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Chapter IV 
DISCUSSION 
 
Previous studies by Ching et al. (2003) identified StarD13 as a tumor suppressor 
gene in hepatocellular carcinoma cells. Later, Kawai et al. (2009) revealed that StarD13 
actually localizes to focal adhesion in HeLa cells. However, in the current study, we 
provide an overall characterization of StarD13 in breast cancer in terms of expression, 
effect on cell proliferation and viability, localization, GAP activity and role in motility 
and invasion. 
Looking at its level of expression by IHC we revealed that StarD13 is highly 
expressed in non-tumor in situ form of breast cancer and it is downregulated in grades I 
and II; confirming its role as a tumor suppressor. This was in accordance with previous 
studies where StarD13 was found to be under-expressed in several cancer types 
including lung, colon, gastric, ovarian, uterine, renal and rectal tumors (Ullmannova & 
Popescu, 2006). However to our utmost surprise, StarD13 showed a relatively high 
expression in highly metastatic forms of breast cancer. This was in accordance with a 
previous study conducted in our lab on astrocytoma where we showed StarD13 to over-
expressed in grades III and IV as compared to grades I and II (El-Sitt, et al., 2012). This 
brought us to the hypothesis that although being a tumor suppressor, StarD13 might be 
needed for cellular motility. Thus, we considered an in vitro model of breast cancer cell 
lines to look at the effect of StarD13 on cellular proliferation and viability. The over-
expression of StarD13 in breast cancer cell lines, using a GFP-construct led to an 
increase in the percentage of dead cells and a decrease in cell viability as determined by 
typan blue exclusion and WST-1 proliferation assay, respectively. Moreover, silencing 
StarD13 using specific siRNAs led to a decrease in cell death and an increase in cellular 
viability. This was consistent with a previous study in our lab done on astrocytoma cell 
lines. In this study, StarD13 was knocked down in astrocytoma cell lines using specific 
siRNA. Trypan blue exclusion method and WST-1 proliferation assay revealed a 
decrease in the percentage of dead cells and a relative increase in cellular viability. 
Conversely, an increase in dead cells and a decrease in cellular viability is observed upon 
transfecting asctrocytoma cells with StarD13-GFP construct (El-Sitt, et al., 2012). 
Therefore, consistent with the literature, StarD13 seems to play a tumor suppressor 
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function in breast cancer cells. However, in order to explain our IHC results, we next 
wanted to determine its probable role in cellular motility.  
In an attempt to explain how the silencing of StarD13 is affecting cellular 
proliferation, we immunnoblotted for p21 and p53 tumor suppressor genes. Our results 
showed that silencing StarD13 down-regulated the level of expression of both p21 and 
p53 proteins. This suggests a possible mechanism by which StarD13 knockdown is 
promoting cellular proliferation through down-regulating p21 and p53 tumor 
suppressor genes.  
As mentioned earlier, previous studies showed that StarD13 harbors a GAP 
domain(Ullmannova & Popescu, 2006) and localizes to focal adhesions (Kawai, et al., 
2009). In our system, we confirmed StarD13 localization to focal adhesions in breast 
cancer cells. Moreover, we showed that it indeed functions as GAP where we observed 
a decrease in the activation of both RhoA and Cdc42 in cells over-expressing StarD13. 
Studies done in hepatocellular carcinoma showed that under-expression of StarD13 was 
associated with an over-expression of RhoA (Xiaorong, Wei, Liyuan, & Kaiyan, 2008) 
thus supporting our findings. These data collectively suggest that StarD13 functions in 
focal adhesion of the cells where it might have a role in regulating RhoA and affecting 
cellular motility.   
Therefore, we were interested to determine first the effect of RhoA itself, on 
breast cancer cell motility. Our data showed that silencing RhoA resulted in the 
inhibition of cell migration. This indicates that RhoA might play a role in breast cancer 
progression and metastasis through contributing to cell motility. Our results are 
consistent with previous studies that showed that RhoA knockdown inhibits cell 
motility and invasion of MDA-MB231 cells (Wu, Wu, Rosenthal, Rhee, & Merajver, 
2010). Vega et al. (2011) also showed that silencing of both RhoA and RhoC inhibited 
cellular motility in breast cancer cells. This implies that RhoA seems to play a positive 
role in promoting breast cancer cell motility. Moreover, inhibition of downstream 
effector ROCK inhibits cell motility in various cell systems (El-Sibai, et al., 2008; Ridley, 
2001; Worthylake & Burridge, 2003).  
Being a GAP for RhoA, we expected that StarD13 might be essential for cellular 
motility in breast cancer. Indeed, knockdown of StarD13 in breast cancer cell lines 
inhibited cell motility. This may explain the increase of StarD13 expression in grades III 
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obtained in IHC and verify our hypothesis that although being a tumor suppressor, this 
protein is needed for motility. Moreover, looking at their morphology, cells were stuck 
unable to detach their tail in order to retract their cell body and move forward (Figure 
20A). This was consistent with previous studies in our lab, where StarD13 knockdown 
inhibited migration of astrocytoma cells. This was also reflected by an increase in 
cellular attachement through stabilization of focal adhesions. Also, StarD13 was shown 
to play an omportant role in the regulation of RhoA activity in astrocytoma cells (data 
not published).  However, contradictory to our results, a previous study on normal 
endothelial cells reported that the inhibition of StarD13 led to an increase in cell 
migration (Y. Lin, et al., 2010). This discrepancy can be explained by the fact that this 
study was conducted in normal cell systems vastly different from breast cancer cells 
used in our study that typically display distinctive cellular morphology and altered 
signaling pathways.   
RhoA has been extensively proven to be indispensible for the formation of focal 
adhesions (Arjonen, et al., 2011; Wolfenson, et al., 2009) and that increasing Rho 
activation stabilizes focal adhesions inhibiting cell motility (Cox, et al., 2001; Sander, et 
al., 1999). Thus, we formulated the hypothesis that StarD13 knockdown is keeping 
RhoA active in focal adhesions and it was of great interest to us to investigate the 
mechanism by which it is affecting cell motility. We started by looking at the dynamics 
of cellular adhesion following Rac and RhoA knockdowns. In cells with Rac 
knockdown, neither focal complexes nor focal adhesions were observed (Figure 21). 
This is in accordance with the fact that Rac is needed for the formation of focal 
complexes (Kaverina, et al., 2002). Moreover, in cell under-expressing RhoA showed 
inability to form mature focal adhesions (Figure 23). Similarly previous studies done on 
MTLn3 cells showed that inhibition of RhoA downstream effector ROCK blocked the 
maturation of focal adhesions in MTLn3 cells (El-Sibai, et al., 2008). However, silencing 
StarD13 led to the stabilization of focal adhesions and decrease in focal complexes 
(Figure 24). Hence, we suspected that cells with StarD13 knockdown, seem to have a 
constitutively active RhoA stabilizing cellular adhesion to the underlying substratum and 
impeding tail retraction resulting in inhibition of cell motility. It is known that the 
completion of the cell motility cycle requires the disassembly of focal adhesions, a 
process involving the inhibition of RhoA. Thus, we suspect that StarD13 actually plays a 
role in inhibiting RhoA leading to the detachment of the cell. Our data is strengthened 
by previous studies done on MDA-MB231 breast cancer cell lines where silencing RhoA 
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led to reduced stress fibers formation and a drastic decrease in focal adhesion formation 
(Wu, et al., 2010).  This hypothesis was also reinforced by the increase of cellular 
adhesion to collagen I upon knocking down StarD13 (Figure 26). Relevantly, Wu et al. 
(2010) showed that silencing RhoA in MDA-MB231 cell lines decreased cellular 
adhesion to collagen I.  
To further strengthen our hypothesis, we suspected that over-expressing a 
dominant active form of RhoA would mimic StarD13 knockdown phenotype in cell 
motility and adhesion. Indeed, transfecting the cells with a constitutively active RhoA 
inhibited cell motility and cells showed larger and more abundant focal adhesions 
relative to focal complexes (Figure 25).  Similar studies involving the use of dominant 
active RhoA have demonstrated an inhibition of cellular motility (Banyard, Anand-Apte, 
Symons, & Zetter, 2000; Li, et al., 2010; Tkach, Bock, & Berezin, 2005; Vial, Sahai, & 
Marshall, 2003). 
After determining the mechanism by which StarD13 might affect random 2D cell 
motility, it was intriguing to us to study its effect on cellular invasion in 3D. For this we 
transfected the cells with siRNA against starD13 and performed collagen-based 
transwell invasion assay. Knowing that StarD13 knockdown inhibited cellular motility in 
2D it was assumed that it would also inhibit cell invasion. However, to our ultimate 
surprise, silencing StarD13 had a positive effect on cellular invasion, despite the fact that 
StarD13 knockdown stabilizes focal adhesions. This might be explained by the 
hypothesis that focal adhesions may play an unconventional role in cellular invasion. In 
fact, a recent report studied the contribution of focal adhesions to matrix degradation. 
Results revealed that several cell lines degraded underlying ECM specifically at focal 
adhesion sites. This process occurred through proteolytic activity of MMPs and not due 
to physical tension exerted by FAs onto the matrix (Y. Wang & McNiven, 2012). 
Moreover, other studies demonstrated that silencing RhoA leads to the inhibition of 
cellular invasion, particularly in breast cancer cell lines (Pille, et al., 2005; Wu, et al., 
2010). This solidifies our data with starD13 knockdown where we typically have an 
increase in RhoA activity, thus promoting cellular invasion. However, as shown by Vega 
et al. (2011) depletion of RhoA in breast cancer cells resulted in the formation of 
elongated protrusions promoting cellular invasion. This implies that this aspect remains 
highly controversial and subject to various discrepancies. Moreover, it was previously 
discovered that in 3D matrices, tumor cells are able to switch between distinct modes of 
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motility (Sahai & Marshall, 2003). This pertains to interplay between different signaling 
requirements. Thus, cells can switch between a rounded blebbing movement and a more 
elongated protrusive fashion. Thus in our study, the depletion of StarD13 increased 
cellular adhesion to the ECM impeding 2D mesenchymal cellular migration; however, 
this was reflected in an increase in 3D movement. This suggests that when cells cannot 
move in an adhesion-dependent manner, they tend to switch to a more amoeboid 
fashion. This is also reflected by interplay between Rho/ROCK dependent and 
independent manner (Sahai & Marshall, 2003). Therefore, the ability of tumor cells to 
switch between modes of motility may limit the effectiveness of prospective inhibitory 
strategies targeting particular cell morphology, hence promoting the selection of a 
different mode to escape inhibition.  
Prospective work includes investigating the mechanism by which StarD13 affects 
cellular viability and proliferation. This includes examining its effect on the cell cycle, in 
which we can actually detect whether StarD13 knockdown effect is through inducing 
cell cycle arrest or promoting cells to undergo apoptosis. Moreover, it would be 
interguing to us to study how StarD13 knockdown is promoting cellular invasion. This 
includes looking at markers for invasive phenotype including the production of MMPs 
and matrix degradation. This also involves examining the formation of invadopodial 
structures and the contribution of focal adhesios in matrix degradation process. This 
could even be taken a step further through the development of an in vivo 3D model and 
studying the role of StarD13 in tumor metastasis and invasion. This includes the role of 
StarD13 in intravasation and the ability of the tumor to reach secondary sites.  
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Chapter V 
CONCLUSION 
 
Although previously known as a tumor suppressor gene product, in the current 
study we described for the first time the role of StarD13 in breast cancer proliferation 
and motility. Our results showed that StarD13 negatively affects cellular proliferation. 
However, having a RhoGAP activity and localizing to focal adhesions of the cell, we 
showed that StarD13 actually plays an essential role in cellular motility. This correlated 
to the increase in its expression in metastatic forms of the tumor.  In this context, 
looking at the dynamics of focal adhesion, StarD13 seemed to be involved in the 
inhibition of RhoA following the maturation of FAs that results in the detachment and 
forward movement of the cell. This is depicted below in our proposed model (Figure 
28). Upon silencing StarD13 using siRNA, cells showed elongated tail morphology with 
stabilized focal adhesions and inhibitory cellular motility. However, this was not 
correlated in 3D mode, where we saw that cells with StarD13 knockdown seemed to 
have an enhanced invasive ability (Figure 29).  
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Figure 28: Model-1: Regulation of cell motility. Rac1 is active at the leading edge of 
the cell driving the formation of actin-rich lamellipodia and focal complexes. StarD13 keeps 
RhoA inactive at the front restricting it to an area behind the leading edge. RhoA is also 
active at the rear end of the cell inducing stress fibers formation. As the cell moves forward, 
RhoA activation causes the maturation of focal complexes into focal adhesions and leads to 
the contraction of the cell body (lower panel). StarD13 plays a role in the inactivation of 
RhoA, driving the disassembly of focal adhesions and allowing tail detachment. 
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Figure 28: Model-2: StarD13 knockdown promotes cellular invasion. Upon 
knocking down StarD13, RhoA is kept highly active forming extensive stress fibers and 
stabilizing focal adhesions. The cell is therefore stuck and cannot move in 2D, this promotes 
transition into a more ameboid phenotype directing the cell towards degrading and invading 
the underlying ECM.  
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